SCHEMBL214295

SCHEMBL214295

Nc1nc2cc(F)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
MASP2 O00187 1/20 0.53
MEN1 O00255 1/20 0.53
NUDT1 P36639 1/20 0.53
KMT2A Q03164 1/20 0.53
AOC3 Q16853 1/20 0.53
FABP6 P51161 2/20 0.50
TYMS P04818 3/20 0.49
BACE1 P56817 2/20 0.47
PLAU P00749 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
TDP1 Q9NUW8 1/20 0.41
IDO1 P14902 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5679441 0.85 MASP2 (0.47) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL1887281 0.84 PLAU (0.61) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL31651401 0.84 PLAU (0.61) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL5679180 0.81 TAAR1 (0.50) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL1170649 0.79 KDM4E (0.52) ALDH1A1ALPLALPIALPGKDM4E
SCHEMBL29449363 0.79 MEN1 (0.57) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL118057 0.79 MEN1 (0.57) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL26075185 0.79 FABP6 (0.59) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL11363764 0.78 ALDH1A1 (0.52) ALDH1A1MASP2MEN1NUDT1KMT2A
Hydrochloric Acid SCHEMBL6621838 0.78 MEN1 (0.55) ALDH1A1MASP2MEN1NUDT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10292390-B2 Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-05-21 US claimed
US-20130136782-A1 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives WISCONSIN ALUMNI RESEARCH FOUNDATION 2013-05-30 US claimed
CN-122079899-A Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein 2026-05-26 CN disclosed
US-20260125348-A1 ARYL HYDROCARBON RECEPTOR ACTIVATORS OREGON STATE UNIVERSITY (US) 2026-05-07 US disclosed
EP-4710922-A2 ARYL HYDROCARBON RECEPTOR ACTIVATORS Oregon State University (US) 2026-03-18 EP disclosed
EP-4003337-B1 ARYL HYDROCARBON RECEPTOR ACTIVATORS UNIV OREGON STATE (US) 2026-03-11 EP disclosed
US-12473262-B2 Aryl hydrocarbon receptor activators OREGON STATE UNIVERSITY (US) 2025-11-18 US disclosed
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-04-11 US disclosed
EP-4269394-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2023-11-01 EP disclosed
CN-114989096-B Thioazole compound and preparation method and application thereof 赣南师范大学 2023-10-24 CN disclosed
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 CN disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof BROWN TRUMAN R 2006-04-27 US disclosed
US-5326779-A Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles THE ROCKEFELLER UNIVERSITY (US) 1994-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 ALDH1A1 4295/4885MASP2 1959/4885MEN1 3504/4885
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof ALDOA, FBP1, GYS2 ALDH1A1 450/4885MASP2 99/4885MEN1 1158/4885
US-20130136782-A1 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives FLNB, BRI3BP, CCNI ALDH1A1 1841/4885MASP2 698/4885MEN1 3710/4885
US-10292390-B2 Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives FLNB, BRI3BP, CCNI ALDH1A1 1841/4885MASP2 698/4885MEN1 3710/4885
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 ALDH1A1 3016/4885MASP2 4005/4885MEN1 700/4885
US-20260125348-A1 ARYL HYDROCARBON RECEPTOR ACTIVATORS AHR, ARNT, NR1H2 ALDH1A1 2105/4885MASP2 3021/4885MEN1 4553/4885
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT SIRT7, SIRT1, BRD7 ALDH1A1 776/4885MASP2 4053/4885MEN1 2217/4885
US-12473262-B2 Aryl hydrocarbon receptor activators AHR, ARNT, NR0B1 ALDH1A1 787/4885MASP2 2416/4885MEN1 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.